New Dual-Action antibody takes on advanced tumors
NCT ID NCT05767060
First seen Dec 29, 2025 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This early-stage trial tested a new drug called BAT7104 in 86 people with advanced cancers that had stopped responding to standard treatments. The drug is a bispecific antibody designed to block two proteins (PD-L1 and CD47) that help tumors hide from the immune system. The main goals were to check safety and find the right dose, while also looking for any signs that the tumors might shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Li Zhang
Guangzhou, Guangdong, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAT7104 injection (a bispecific antibody targeting PD-L1 and CD47)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors. Results may not apply to all cancer types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.